XML 29 R1.htm IDEA: XBRL DOCUMENT v3.25.4
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Feb. 27, 2026
Jun. 30, 2025
Document and Entity Information [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2025    
Document Transition Report false    
Entity File Number 001-39580    
Entity Registrant Name IMMUNOME, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 77-0694340    
Entity Address, Address Line One 18702 N. Creek Parkway    
Entity Address, Address Line Two Suite 100    
Entity Address, City or Town Bothell    
Entity Address State Or Province WA    
Entity Address, Postal Zip Code 98011    
City Area Code 425    
Local Phone Number 939-7410    
Title of 12(b) Security Common Stock, $0.0001 Par Value    
Trading Symbol IMNM    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 728.5
Entity Common Stock, Shares Outstanding   113,133,199  
Documents Incorporated by Reference [Text Block]

Portions of the registrant’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting of Stockholders to be filed with Securities and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10‑K, are incorporated by reference into Part III, Items 10-14 of this Form 10‑K.

    
Auditor Firm ID 42    
Auditor Name Ernst & Young LLP    
Auditor Location Philadelphia, Pennsylvania    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Immunome, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.

    
Entity Central Index Key 0001472012    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Amendment Flag false